Xanthistop 120

Xanthistop 120

Description:

Xanthistop 120 mg is an oral prescription medicine containing febuxostat, a xanthine oxidase inhibitor used to lower high uric acid levels in the blood. It is indicated for the long‑term management of chronic hyperuricaemia in patients with gout where urate crystal deposition has already occurred (such as gouty arthritis or tophi). By selectively inhibiting xanthine oxidase, Xanthistop 120 reduces uric acid production, helping to prevent gout flares and long‑term joint damage when used regularly under medical supervision.

Indications:

• Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (e.g. history of gouty arthritis, presence of tophi).
• Long‑term management of elevated serum uric acid levels associated with gout.
• Helps reduce the frequency and severity of gout attacks when used continuously.
• Prevention of complications related to persistent high uric acid, such as joint damage and urate crystal deposits, as part of a comprehensive gout management plan.

Active Ingredients / Key Components:

• Febuxostat – 120 mg per tablet.
• Other tablet excipients (fillers, binders, coating agents, preservatives) – exact composition and concentrations are not specified in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.). Please refer to the official package leaflet for the full excipient list.

Dosage & Administration / How to Use:

• Recommended dose for adults: 1 tablet of Xanthistop 120 mg once daily, or as directed by your physician.
• Tablets are taken orally with water and can be taken with or without food.
• Use regularly every day at the same time to maintain stable uric acid reduction; do not use only during an acute attack.
• Do not exceed the prescribed dose. Dose adjustments may be required in certain patients based on clinical response and medical history, as determined by the physician.
• If you miss a dose, take it as soon as you remember on the same day. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.
• Therapy is usually long term. Do not stop treatment without consulting your doctor, even if symptoms improve, as uric acid levels may rise again.
• Not recommended for use in children and adolescents unless specifically prescribed by a specialist, as safety and efficacy data in this age group are limited.

Clinical Benefits:

• Effectively lowers serum uric acid levels by inhibiting xanthine oxidase, the key enzyme responsible for uric acid production.
• Helps prevent recurrent gout attacks when used consistently as maintenance therapy.
• Supports reduction of urate crystal deposits and tophi over time, contributing to improved joint function and comfort.
• May help limit long‑term joint damage and disability associated with uncontrolled chronic gout.
• Once‑daily dosing supports better treatment adherence and convenient long‑term management of hyperuricaemia.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity or allergy to febuxostat or any of the tablet excipients.
• Not recommended in patients being treated with azathioprine, mercaptopurine or theophylline unless under strict specialist supervision, due to potential serious interactions.
• Use with caution in patients with a history of major cardiovascular disease (such as heart attack, stroke, or unstable angina); discuss risks and benefits with your doctor.
• Use with caution in patients with severe renal or hepatic impairment; dose adjustment or alternative therapy may be required.
• During the initial months of therapy, gout flares may increase as uric acid levels change; your doctor may prescribe additional medicines (e.g. colchicine or NSAIDs) to prevent or manage flares.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Febuxostat should only be used if the potential benefit justifies the potential risk.
• Inform your doctor about all other medicines you are taking, including over‑the‑counter drugs and supplements, to avoid interactions.
• If you develop signs of severe skin reactions (such as widespread rash, blistering, peeling, or mucosal lesions), stop the medicine immediately and seek urgent medical attention.
• If you experience chest pain, shortness of breath, sudden weakness, difficulty speaking, or other symptoms suggestive of cardiovascular events, seek emergency medical care.
• Not intended to diagnose, treat, cure, or prevent any disease without proper medical supervision; it must be used only under a doctor’s prescription.
• Keep out of reach of children.

Side Effects:

• Common side effects may include headache, dizziness, nausea, diarrhea, abdominal pain, joint pain, and mild rash.
• Gout flares can occur, especially at the start of treatment, as uric acid levels begin to fall. This does not mean the medicine is not working; your doctor may recommend preventive therapy.
• Less common but serious side effects may include severe skin reactions, liver function disturbances (e.g. elevated liver enzymes, hepatitis), allergic reactions (swelling of face, lips, tongue, or throat; difficulty breathing), and cardiovascular events.
• Stop taking the medicine and seek immediate medical attention if you notice signs of severe allergic reaction, severe skin rash, yellowing of the skin or eyes, dark urine, persistent nausea/vomiting, chest pain, sudden shortness of breath, or neurological symptoms such as sudden weakness or difficulty speaking.
• Always report any unusual or persistent symptoms to your healthcare provider for proper evaluation.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Strength: 120 mg febuxostat per tablet.
• Form: Oral tablets.
• Pack size: 30 tablets per pack (sufficient for approximately 1 month of once‑daily therapy, depending on prescribed duration).
• Intended use: Prescription medicine for adults for the long‑term management of chronic hyperuricaemia associated with gout.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.